Breaking Free from Corticosteroids in Crohn’s Disease
This editorial discusses the post-hoc analysis by Dubinsky et al. evaluating upadacitinib's efficacy and safety by baseline corticosteroid use in Crohn's disease, highlighting its corticosteroid-sparing potential, the need for standardized tapering in trials, and the implications for achieving durable corticosteroid-free remission.
Authors
- Raquel Oliveira (ORCID: https://orcid.org/0000-0002-3818-981X)
- Joana Roseira (ORCID: https://orcid.org/0000-0002-5098-8729)
Institutions
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Algarve Biomedical Center (PT)
- University of Algarve (PT)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1093/ibd/izaf274
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00